

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**


Cell-Specific Adenovirus

Fig. 1A



2/42

Fig. 1B



3/42

Taxol (0.625 nM) + CV787 (MOI=0.01)




Fig. 2

4/42

Taxotere (3.12 nM) + CV787 (moi=0.01)




Fig. 3

5/42

CV787 (moi=0.01) + Taxotere (3.12nM)




Fig. 4

6/42

Mitoxantrone (100 nM) + CV787 (moi=0.1)





Fig. 5

7/42

Etoposide (500 ng/ml) + CV787 (moi=0.01)



Treatment Fig. 6

CV787 (moi=0.01) + Doxorubicin (50 ng/ml)




Fig. 7

9/42

Cisplatin (8.25 μ M) + CV787 (moi=0.1)




Fig. 8

FOSTOT 25E4T860

5-Fluorouracil (35 μ M) + CV787 (moi=0.01)




Fig. 9

CV787 (moi=0.01) + ^{137}Cs (2 Gy)

11/42




Fig. 10

12/42

Virus Yield (LNCaP)




Fig. 11

13/42




Fig. 12

14/42

Taxol Does not Alter CV787's Specificity




Fig. 13

Days After Treatment

—■— 293 —●— LNCaP —▲— HBL-100 —◆— OVCAR-3

15/42

Specificity of CV787 + Mitoxantrone




FIG. 14

CV790 0.01moi/Doxorubicin 10ng/ml

16/42




Fig. 15

17/42

10ng/ml Doxorubicin first,
 then 0.01 MOI CV790




Fig. 16

18/42

0.01 MOI CV790 and 10ng/ml Doxorubicin together




Fig. 17

19/42

CV790 0.1moi/Cisplatin 1ug/ml




Fig. 18

20/42

CV790 0.1moi/Taxol 0.5ng/ml




Fig. 19

CV790 0.1moi/5-FU 10ng/ml




Fig. 20

CV790 0.1moi/Mitoxantrone 4ng/ml

22/42




Fig. 21

23/42

CV790 0.1moi/Mitomycin C 10ng/ml




Fig. 22

24/42

Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




Fig. 23

Weeks After Treatment

—◆— Control —△— CV787, 10⁷p/mm³ —●— Taxol, 15 mg/kg —■— CV787/Taxol

25/42




Fig. 24

Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




Fig. 25

27/42

Tumor Volume of LNCaP Xenograft Treated with CV787 and Mitoxantrone




Fig. 26

28/42

Tumor Volume of LNCaP Xenografts Treated with CV787 and Estramustine




Fig. 27

29/42

LNCaP Xenograft Treated with CV787 and Docetaxel




Fig. 28

Weeks After Treatment

30/42

LNCaP Xenograft Treated with CV787 and Docetaxel




Fig. 29

31/42

Tumor Volume of Hep3B Treated with CV790 and Doxorubicin




Fig. 30

Tumor Volume of Hep3B Xenograft Treated with CV890 and Doxorubicin

32/42





Fig. 31

33/42

Cell Viability

Radiation (6Gy) + CV787(moi=0.1)



Days After Treatment




Fig. 32

34/42




Fig. 33

35/42




Fig. 34



36/42

Virus Yield Radiation (6Gy) + CV787(moi=0.1)




Fig. 35

—●— CV787 —■— Radiation+CV787

37/42




Fig. 36

38/42

FIG. 37

G ATG ACC GGC TCA ACC ATC GCG CCC ACA ACG GAC TAT CGC AAC ACC
46
Met Thr Gly Ser Thr Ile Ala Pro Thr Thr Asp Tyr Arg Asn Thr
1 5 10 15
ACT GCT ACC GGA CTA ACA TCT GCC CTA AAT TTA CCC CAA GTT CAT GCC
94
Thr Ala Thr Gly Leu Thr Ser Ala Leu Asn Leu Pro Gln Val His Ala
20 25 30
TTT GTC AAT GAC TGG GCG AGC TTG GAC ATG TGG TGG TTT TCC ATA GCG
142
Phe Val Asn Asp Trp Ala Ser Leu Asp Met Trp Trp Phe Ser Ile Ala
35 40 45
CTT ATG TTT GTT TGC CTT ATT ATT ATG TGG CTT ATT TGT TGC CTA AAG
190
Leu Met Phe Val Cys Leu Ile Ile Met Trp Leu Ile Cys Cys Leu Lys
50 55 60
CGC AGA CGC GCC AGA CCC CCC ATC TAT AGG CCT ATC ATT GTG CTC AAC
238
Arg Arg Arg Ala Arg Pro Pro Ile Tyr Arg Pro Ile Ile Val Leu Asn
65 70 75
CCA CAC AAT GAA AAA ATT CAT AGA TTG GAC GGT CTG AAA CCA TGT TCT
286
Pro His Asn Glu Lys Ile His Arg Leu Asp Gly Leu Lys Pro Cys Ser
80 85 90 95
CTT CTT TTA CAG TAT GAT TAA
307
Leu Leu Leu Gln Tyr Asp
100

09814357.101501

39/42




Fig. 38




Fig. 39

41/42




Fig. 40

FIG. 40

Structure of CV876, CV882 and CV884

42/42




Fig. 41